Molecular Biomedicine Introduction
2019-11-09
Open the phone and scan
Introduction of Molecular Biomedicine
Chief
Editor
Prof. Arnold JM Driessen
Molecular Biomedicine is a peer-reviewed, online open access (OA), multidisciplinary journal that publishes the pioneer works of biomedicine, emphasizing on pathogenic mechanism and innovative techniques for diagnosis and therapy. It adopts a "quick passage" model for original achievements to help authors get their papers published quickly with a minimum time of only one week for review and acceptance. From 2020 to 2022, the article processing charge (APC) will be waived.
Editor-in-Chief
Arnold JM Driessen
Groningen Biomolecular Sciences and
Biotechnology Institut, University of
Groningen
Professor
at the University of Groningen, former director of Groningen Biomolecular
Sciences and Biotechnology Institute, and one
of the founders of the Center for Synthetic Biology and the Center for
Sustainable Antibacterial (CESAM) both in Groningen. A member of
the Royal Netherlands Academy of Arts and Sciences. Chairman of the Dutch
Society of Biochemistry and Molecular Biology. Member of consortium
assembly of Building a Synthetic Cell (BaSyc). He has received awards
including the Kluyver Award of KNVM and the FEBS Anniversary Prize of the
Society for Biological Chemistry. He also serves as managing
editor of Extremophiles, and chaired several conferences of the European
Science Foundation, European Molecular Biology Organization, and Gordon
Research Conference. He has authored more than 460 research papers,
authored and edited two books, and (co-)invented 11 patents. Prof. Driessen is an outstanding scientist whose papers are highly cited (over 32,000 times)
with an academic h-index of 97.
Yuquan Wei
State Key Laboratory of Biotherapy and
Clinical Cancer Center, West China Hospital, Sichuan University, China
Ph.D., Professor and Director
of National/State Key Laboratory of Biotherapy and Clinical Cancer Center, West
China Hospital, West China Medical School, Sichuan University, Chengdu,
academician of Chinese Academy of Sciences. He was educated at West China
University of Medical Sciences for a bachelor's degree in Medicine and a
Master's Degree in Medicine, and educated at Kyoto University in Japan for a
Doctoral Degree. His major research interests
include targeted therapy, signal transduction, gene and cell therapy, and
cancer vaccines. He has published more than 300 papers in international
journals including Nature, Nat Med, Nat Commun, PNAS, Blood, Cancer Res, Clinic Cancer Res, J Immunol, and J Biol Chem, etc. He is now President of China Medicinal Biotech
Association. He has served as the cheif editor of Signal Transduction and Targeted
Therapy, an associate editor of Human Gene Therapy and Editorial Board Member of several
International Journals.
